PURPOSE. We determined the phenotypic variation, disease progression, and potential modifiers of autosomal dominant retinal dystrophies caused by a splice site founder mutation, c.828þ3A>T, in the PRPH2 gene.
M utations in the PRPH2 gene (OMIM:179605) are known to cause a wide range of autosomal dominant retinal dystrophies (adRD; phenotype MIM: 613105, 608133, 169150, 608161, 608133, 136880), but the source of this variation is poorly understood. We previously identified a PRPH2 (NM_000322.4) splice site mutation, c.828þ3A>T, in numerous patients with retinal dystrophies. 1 Haplotype analysis revealed that the mutation derives from a common ancestor and its prevalence is due to a founder effect. 2 Individuals with the c.828þ3A>T mutation express a PRPH2 splice variant that was not found in controls and is consistent with abnormal splicing. Clinical diagnoses in individuals with this mutation range from pattern dystrophies (PD) to retinitis pigmentosa (RP), cone-rod dystrophy (CRD), and/or unspecified macular dystrophy. 2 This phenotypic variation is comparable to other mutations in PRPH2, for example, a 3-bp deletion of codon 153, and a P210R missense change 3 that were reported to cause multiple phenotypes within the same nuclear families. 4 Another PRPH2 mutation, R172W, also exhibits a founder effect but with similar phenotypes in most families, 5, 6 although intrafamilial variation also has been described in two families. 7, 8 In this study, we evaluated clinical records, fundus photographs, and visual function data to characterize the phenotype of the PRPH2 c.828þ3A>T splice site mutation. Due to the founder effect, this cohort is particularly well suited for identifying possible causes of variation that are not in cis to the splice site mutation.
Peripherin/PRPH2 is a photoreceptor-specific membrane protein that homodimerizes with itself. Polymorphic protein haplotypes in trans were considered as modifiers of dominant diseases because the two alleles are expressed at the same time in the same tissues, translation is concurrent, and protein iovs.arvojournals.org j ISSN: 1552-5783 products may follow identical pathways and interact directly. Therefore, sequence variants in the PRPH2 gene in trans that code for polymorphic protein isoforms (haplotypes), Glu 304 -Lys 310 -Gly 338 (G 910 -A 929 -G 1013 ), Gln 304 -Arg 310 -Asp 338 (C 910 -G 929 -A 1013 ), and Gln 304 -Lys 310 -Asp 338 (C 910 -A 929 -A 1013 ), coded by three polymorphic cSNPs, rs390659 c.910G>C (GAG->CAG) p.Glu304Gln, rs425876, c.929A>G (AAG->AGG) p.Lys310Arg, and rs434102 c.1013G>A (GGC->GAC) p.Gly338Asp were considered as potential modifiers of the disease phenotype. 2, 9, 10 We also considered 3 other candidate genes as modifiers, ROM1, GUCA1A, and NXNL1. ROM1 is a photoreceptorspecific gene that encodes a rod outer-membrane protein localized to the photoreceptor outer segment disk membranes. It has 35% homology to PRPH2 and interacts with PRPH2-forming heterotetramers. 11 Mutations in this gene alone have not been shown conclusively to cause any retinal disease, although a digenic form of RP with a PRPH2 mutation has been reported. 12 Therefore, ROM1 was considered as a strong candidate modifier gene, particularly in individuals with the retinitis pigmentosa phenotype. The GUCA1A gene encodes a photoreceptor-specific guanylate cyclase-activator protein, a novel Ca(2þ) binding protein that stimulates synthesis of cGMP in photoreceptors. 13 Mutations in this gene are known to cause autosomal dominant cone dystrophy, making it a likely modifier gene. 14, 15 Another gene, NXNL1, encodes a thioredoxin-like protein 6, which is specifically expressed in photoreceptors and required for cone viability. 16 We considered GUCA1A and NXNL1 as potential modifier genes, especially in those patients exhibiting predominant macular disease and cone loss.
METHODS

Subjects and Clinical Studies
All subjects were ascertained in the United States after obtaining written informed consent and all procedures conformed to the Declaration of Helsinki and were approved by the Institutional Review Board (IRB) board of each respective institution as described previously. 2 
Visual Acuity
Best-corrected visual acuity was recorded using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart or standard Snellen visual acuity charts.
Visual Fields
Visual fields were tested at RFSW using standard spot size 3, program 30-2 and/or 60-4 SITA Fast on a Humphrey field analyzer (Humphrey Instruments, Inc., San Leandro, CA, USA).
Electrophysiology
Patients were dilated using tropicamide 1% and phenylephrine 2.5% and then dark-adapted for 45 minutes before testing. Usually only the eye with the poorer visual acuity was tested. The ERG was recorded from the dilated, dark-adapted eye following the International Society for Clinical Electrophysiology of Vision (ISCEV) standards as described previously. 17 
Dark Adaptometry
Patients' eyes were dilated using tropicamide 1% and phenylephrine 2.5% and dark-adapted completely for 45 minutes before testing. Final dark-adapted thresholds were measured on a Goldmann-Weekers adaptometer according to standard protocols. [18] [19] [20] 
Fundus Photographs
Fundus photographs were obtained from each site whenever available. Phenotypic classification was based on fundus findings available in 62 individuals. All individuals with macular and/or peripheral yellow, orange, or gray (dot and halo) deposits were grouped into various types of PD as described previously. [21] [22] [23] Patients with macular pigmentation and atrophy preceding peripheral retinal changes were classified as having CRD. 24 If the fundus appeared to have peripheral intraretinal bone spicules, mottling, and granularity of the RPE, and/or had optic nerve pallor and retinal vessel attenuation, patients were classified as having RP. 25 Individuals with symmetric, sharply outlined areas of geographic atrophy of the RPE and choroid, approximately 3 to 4 disc diameters in size, and having a yellow-white appearance of the choroidal vessels, were classified as central areolar chorioretinal dystrophy (CACD). 26 These diagnoses were combined into two groups to analyze the effect of modifier genes: Group I -milder phenotype with PD: The presence of yellow or pigmented lesions in the retina and/or retinal atrophy confined to the macula alone; and Group II -more severe phenotype with CRD, RP and CACD: These were characterized by photoreceptor loss, RPE, and choroidal atrophy extending outside the macula and/or presence of intraretinal bone spicules.
Molecular Studies
DNA extraction and screening by SSCP or bidirectional fluorescent di-deoxy sequencing of the genes, PRPH2 (NM_000322.4), ROM1 (NM_000327.3), GUCA1A (NM_000409.3), and NXNL1 (NM_138454.1) were performed using standard conditions as described previously.
1,27 PRPH2 haplotypes in trans were determined by subtraction of the known c.828þ3A>T haplotype from the genotype determined via sequencing. Primers used in the study are available in Supplementary Table S1 .
Statistical Analysis
Linear regression was used to analyze the relation between age and visual function parameters in patients with the splice site PRPH2 mutation. The best-fit values of the slope and intercept, along with their standard errors and 95% confidence intervals (CIs), were calculated. Associations between the two phenotype groups and the three protein haplotypes in trans were tested by Fisher's exact probability test. To confirm that significant associations were not due to age differences or familial clustering of genotypes, generalized estimating equation (GEE) models 28 were fit using the ''geepack'' R package. 29 These regressions modeled phenotype group as a function of haplotype and age via a logistic link, and robustly accounted for genetic correlation within families. An exchangeable correlation structure was specified for each familial cluster, but it is important to note that GEE models are robust even if the correlation structure is misspecified. For all haplotype analyses, we excluded all individuals younger than 43 years, taking into consideration the fact that the youngest age of an individual with the more severe phenotype in our cohort was 43 years.
RESULTS
The presenting symptoms of the individuals with the c.828þ3A>T splice site mutation include reduced, altered, or distorted central vision, sensitivity to bright lights, and reduced night vision. Four distinct phenotypes were observed consistent with PDs, CRD, RP, or CACD with extensive intra-and interfamilial variation. Three types of PD, adult-onset vitelliform macular dystrophy (AVMD), butterfly-shaped macular dystrophy (BMD), and adult-onset flavimaculatus-like macular dystrophy (AOFMD) of three individuals in their 40s are shown in Figures  1A through 1C . Individuals having AVMD and BMD exhibited a milder phenotype at age 40 than the individual with AOFMD, who showed more severe ERG and field loss at age 28 years. A fluorescein angiogram shows hyperfluorescent lesions that are not visible by ophthalmoscope (Fig. 1C, inset) . The absence of ''dark choroid'' distinguishes these from Stargardt's and fundus flavimaculatus caused by mutations in the ABCA4 gene. 30 Individuals with more extensive vision loss, as in CRD, CACD, and RP phenotypes, are shown in Figures 2A through 2C .
The fundus features of 62 individuals, along with their diagnoses, age, and sex, and the PRPH2 mini-haplotypes in trans, are shown in Table 1 and pedigrees for 14 families are available in the Supplementary Material. Of the individuals, 44 were graded as Group I and had the clinical diagnosis of PD, and 18 were graded as Group II and had CRD, RP, or CACD.
Age
The age range of our patients was 16 to 90 years, with majority in the 40-to 50-year range. The youngest individual examined, a 16-year-old male, had minimal yellow lesions in the peripheral retina and the oldest individual, a 90-year-old female, had geographic atrophy in the macula; both belonged to the same family. The majority of the individuals with the splice site mutation fell into the PD Group I (44), with ages ranging from the 20s to the 70s (Table 1) . Individuals having a fundus appearance suggestive of CRD (8), RP (6), and CACD (4) were in their fifth to sixth decades of life (Table 1) .
Visual Acuity
Visual acuity data were available for 46 individuals with the splice site mutation, and the best-corrected visual acuity of the better eye was used for plotting (Fig. 3A) . Most of the PD patients retain fairly good visual function, with their acuity remaining above 20/40 (0.5) until 65 years of age (green symbols). There was a modest decrease of visual acuity in PD with age due to photoreceptor and RPE atrophy in the macular region (Fig. 3A, solid line) . In contrast, patients with CACD and CRD exhibited significantly lower visual acuity (red symbols), with more than half of the patients over age 45 having VA below 20/100 (0.2). Retinitis pigmentosa patients had VA ranging from 20/40 to 20/400 (0.2 to <0.08). 
Visual Fields
Humphrey visual fields were available in 10 individuals. Individuals with PD had better visual fields than those with CRD, CACD, or RP (Figs. 1, 2) . Individuals with vitelliform-like PD had the most well-preserved visual fields (Fig. 1A) . Butterfly-type PD (Fig. 1B) and flavimaculatus-like PD (Fig.  1C) showed preserved central and mild to moderate peripheral field loss. The CRD and CACD patients had central and paracentral scotoma (Figs. 2A, 2B ) and RP patients had primarily peripheral visual field loss progressing to loss of central visual fields as expected (Fig. 2C) .
Dark Adaptometry
Final dark-adapted thresholds were available from 24 patients (Fig. 3B) . The majority of patients with PD (green symbols) had thresholds near the upper limit of normal. Thresholds were elevated approximately 2 to 4 log units above normal in individuals with the RP, CRD, and CACD phenotypes (red symbols).
Electrophysiology
Electroretinographic data were available for 25 individuals, with many patients tested on multiple occasions. Summary ERG parameters are shown in Table 2 and Figure 3 . In general, cone responses were affected less than rod responses. As shown in Figure 3C , patients with PD showed a gradual loss with age of cone amplitude to 30 Hz flicker. The solid green curve is the regression line for cone amplitudes as a function of age on the first visit only. Lines connecting green symbols show repetitive measures on the same individual, with mild decline evident between visits, especially after 40 years of age. In contrast, red symbols show that patients with CRD, CACD, and RP typically had smaller cone amplitudes than patients with PD. Cone b-wave implicit times showed greater delays in patients with more widespread disease than in patients with PD, where cone implicit times were only slightly delayed. Figure 3D shows rod amplitudes as a function of age. All individuals with rod amplitudes significantly below normal (P < 0.05), with the exception of one individual with PD, had RP, CRD, or CACD (red symbols). Individuals of various subgroups of PD did not show any characteristic pattern of photoreceptor loss. Two individuals who had normal and near-normal amplitudes had vitelliform-like PD (Fig. 1A, #5790 ) and butterfly-like PD (Fig. 1B, #214 ). These findings suggested that, although the distribution of flecks results in a varied fundus appearance, the photoreceptor loss does not correspond to fundus appearance.
Long-term follow-up of some individuals over several years show differences in severity of progression. Patients with PD showed milder progressive vision loss (Fig. 4) than patients with CACD/RP-like phenotype (Fig. 5) .
Modifier Gene Screening
Peripherin/PRPH2. The distribution of PRPH2 (NM_000322.4) haplotypes in trans for PD, CRD, CACD, and RP phenotypes are shown in Tables 3 and 4 (Table 4) . A significant difference in the haplotype distribution between the two phenotypic groups among individuals older than 43 years was seen using Fisher's exact probability test (P ¼ 0.0092). A GEE analysis that accounted for differences in age and familial correlation of genotypes confirmed that the increased frequency of the Glu 304 -Lys 310 - Amplitudes (amp) are in microvolts, and implicit times (IT) are in milliseconds. 
DISCUSSION
This study demonstrated that the c.828þ3A>T splice site mutation in the PRPH2 gene is the primary cause of retinal disease in all 62 affected individuals in these 19 families with complete penetrance but highly variable expressivity. It results in clinically diverse, autosomal dominant retinal dystrophies, including PDs, CRD, CACD, and RP (Figs. 1, 2) , in 19 families derived from a common ancestor. 2 The phenotypes fall into two broad clinical categories: Individuals in Group I (N ¼ 44; AVMD, BMD, and AOFMD types of PD) have milder disease than individuals in Group II (CRD, CACD, and RP). There is limited progression from Groups I to II. In our cohort, almost all individuals had reduced photoreceptor responses relative to age-matched controls, regardless of the phenotype (Fig. 3) .
We previously had established a founder effect for the PRPH2 c.828þ3A>T mutation by haplotype analysis which 
